MRP1蛋白表达情况与乳腺癌新辅助化疗疗效的关系

The relationship between the expression of MRP1 protein and treatment effect of neoadjuvant chemotherapy in breast cancer

目的探讨多药耐药相关蛋白1(MRP1)蛋白表达与乳腺癌患者新辅助化疗临床疗效的关系。方法选取实施新辅助化疗的150例患者的临床资料进行回顾性分析,根据化疗效果分为有效组105例及无效组45例,对比两组患者化疗前乳腺癌组织中MRP1蛋白的表达水平,并采用多因素分析法探讨MRP1蛋白表达与乳腺癌患者新辅助化疗效果的关系。结果有效组患者的MRP1蛋白阴性表达率18.10%、弱阳性表达率40.95%、中阳性表达率34.29%、强阳性表达率6.67%,无效组患者的MRP1蛋白阴性表达率6.67%、弱阳性表达率26.67%、中阳性表达率40.00%、强阳性表达率26.67%,两组比较差异有明显统计学意义(P﹤0.01);非条件Logistic回归分析结果显示TNM分期增高、组织学分级低分化、MRP1蛋白阳性表达是乳腺癌患者化疗效果不佳的独立危险因素(P﹤0.05)。结论 MRP1蛋白阳性表达是乳腺癌患者新辅助化疗效果不佳的独立危险因素。

Objective To investigate the relationship between the expression of multidrug resistance associated protein 1（MRP1） and neoadjuvant chemotherapy in breast cancer. Method 150 patients who accepted neoadjuvant chemotherapy were included in the retrospective analysis, according to the outcome of neoadjuvant chemotherapy, 105 patients were responsive to the treatment while another 45 patients were not. The expression level of MRP1 protein in breast cancer tissues were compared between the two groups before chemotherapy, and the relationship between MRP1 protein expression and the effect of neoadjuvant chemotherapy was analyzed by multivariate regression. Result The negative expression rate of MRP1 protein in responsive patients was 18.10%, while 40.95% were with weakly positive expression,34.29% with moderately positive expression and 6.67% with highly positive expression, respectively. In unresponsive patients, the negative expression rate was 6.67%, while weakly, moderately and highly positive expression rate were26.67%, 40.00% and 26.67%, respectively, with significant differences detected between the two group（P〈0.01）. Nonconditional Logistic regression showed that high TNM stage, poor histological differentiation, and positive expression of MRP1 protein were independent risk factors of unresponsiveness to chemotherapy in breast cancer patients（P〈0.05）.Conclusion The positive expression of MRP1 protein may be a risk factor of poor outcome in breast cancer patients who accepted neoadjuvant chemotherapy.